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arteether, a rapidly acting, highly potent antimalarial drug for the treatment of acute Plasmodium
falciparum malaria. Six different crystal forms were prepared utilizing various polar and non-polar
solvents. Scanning electron microscopy (SEM) revealed differences in the surface characteristics of
the six forms from those of a commercial sample. Differential scanning calorimetry (DSC) revealed
the absence of a desolvation endotherm indicating that the forms were neither hydrates nor
solvates. Powder X-ray diffraction (PXRD) patterns of the forms showed much weaker major
peaks than in the commercial sample indicating them to be less crystalline. Solubility and
dissolution studies showed that the most amorphous form was the most soluble and possessed
the highest antimalarial activity.
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The majority of drugs are marketed as solid dosage forms
containing drug in a crystalline state1. The formation of this
crystalline state is subject to a phenomenon known as poly-
morphism whereby different crystal forms are produced depend-
ing on solvent, temperature and crystallization conditions2. Thus,
the crystal habit of a drug is an important variable in pharma-
ceutical manufacturing. A number of basic physicochemical
properties such as solubility3, dissolution rate and melting
behavior, and certain micromeritic properties or performance
characteristics such as tablet compressibility, mechanical strength4
and powder ﬂow depend on the crystal habit of a particular
drug5. The search for the crystal form with the best combination
of solubility and stability6–8 with all its associated intellectual
property issues9 is therefore of crucial importance in the devel-
opment of a new chemical entity and one of the most active areas
of pharmaceutical research10.
The physicochemical properties of a particular crystal form
have an important effect on how it is processed into a drug
product. For instance, the solubility affects the dissolution
rate and possibly the mass transport of a drug and therefore is
an important factor in how the active drug is absorbed from
its dosage form11–13. Those who are involved in the industrial
production and marketing of a product line need to know not
only the exact nature of the material being processed but also
its long-term stability and how its chemical and physical
properties are affected by its crystal form10. The aim of the
present work was to investigate the different crystal forms of
arteether, a poorly soluble drug (17 mg/mL at room tempera-
ture) used to treat cerebral malaria and as a second line
treatment for chloroquine resistant malaria14–16. Various
crystal forms were characterized in terms of their solubility
and dissolution behavior in order to select the form with
optimum physicochemical properties and in vivo pharmacolo-
gical activity.2. Materials and methods
Arteether was generously provided by IPCA Laboratories,
Mumbai, India. Analytical grade methanol, ethanol, dichlor-
omethane, DMSO, toluene and THF were obtained from
Sigma Aldrich, USA, and used as received.
2.1. Preparation of crystal forms
Crystal forms I and VI were prepared by recrystallizing
arteether from hot saturated solutions of dichloromethane
(DCM) and toluene, respectively. Forms II and III were
prepared by adding hot water as antisolvent to saturated
solutions of drug in THF and methanol, respectively. Form IV
was obtained by rotary evaporation of a solution of drug in
ethanol at 80 1C under vacuum. Form V was prepared by
recrystallizing the drug from a mixture of DMSO:H2O (70:30).
2.2. Characterization
2.2.1. Differential scanning calorimetry
DSC thermograms were obtained using a DSC Q20 (TA Instru-
ments-Waters LLC, USA). The calorimeter was calibrated for
temperature and heat ﬂow using the melting point of pure indium(156.6 1C with DH of 25.45 J/g). A mass of 2–8 mg was placed in
the aluminum pan, covered with a lid and sealed. DSC curves
were obtained under a nitrogen purge of 50 mL/min at a heating
rate of 10 1C/min over the temperature range of 50–350 1C.
2.2.2. Scanning electron microscopy
Photomicrographs of the different forms of arteether were
obtained using a Jeol JSM-6100 scanning electron microscope.
Samples were mounted on a metal stub with an adhesive and
coated with gold under vacuum.
2.2.3. X-ray powder diffraction
Powder diffraction patterns were recorded on an X-ray
diffractometer (XPERT-PRO, PANalytical, Netherlands) with
copper as tube anode. Diffractograms were recorded using
voltage 40 kV, 35 mA, angular range 5 and ﬁxed divergence
slit. Care was taken to avoid changes in crystal form during
sample preparation. Samples (approximately 200 mg) were
loaded into the sample holder taking care to avoid any
preferred orientation of the crystals.
2.2.4. Fourier transform infrared spectrometry
FT-IR spectra were obtained using a Mode Spectrum RXI
FT-IR spectrometer (Perkin Elmer, England) over the range
400–4000/cm. Dry KBr (50 mg) was ﬁnely ground in an agate
mortar after which the sample (1–2 mg) was added and gently
mixed. A manual press was used to form pellets.
2.2.5. Dissolution study
Dissolution studies were carried out for 4 h at 3770.5 1C
using phosphate buffer (pH 7.0):methanol (2:1) (500 mL) as
dissolution media in a paddle apparatus-12 equipped with
paddles rotating at 50 rpm. After introducing an appropriate
amount of sample, aliquots were withdrawn after 5, 10, 15, 20,
25, 30, 45, 60, 90, 120, 150, 180, 240 and 300 min and analyzed
by UV spectrometry at 240 nm using a calibration curve of
arteether in methanol:phosphate buffer (pH 7.0) (2:1). Each
dissolution study was performed in duplicate batches.
2.2.6. Aqueous solubility determination
An MSW-275 shaker (Macro Scientiﬁc Works, New Delhi)
was used to measure aqueous solubility of the different forms
of arteether. Solubility studies were performed by adding
50 mg sample and methanol:phosphate buffer (pH 7.0) (2:1)
and shaking at 37 1C for 24 h. Aliquots were removed, ﬁltered
through a 0.45 mm membrane ﬁlter and analyzed by UV
spectrometry at 240 nm as described above.
2.2.7. Solution calorimetry
Enthalpy of solution (DHsol) of the various crystal forms was
determined in phosphate buffer (pH 7):acetonitrile (3:1) using
an isoperibol solution calorimeter model 4300 (Calorimetry
Science Corporation, Utah, USA). This is a semi-adiabatic
calorimeter with temperature resolution after noise reduction
close to 1 mK corresponding to a heat resolution of 1–4 mJ in
a 25 mL buffer (pH 7) reaction vessel. Details are given in our
previous papers17,18. The performance of the system was
validated by showing that DHsol of potassium chloride
(17.301 kJ/mol) in triply distilled water was in good agreement
with the known value of 17.322 kJ/mol. The precision of an
Investigation and characterization of various crystal forms of arteether 131individual measurement was better than 70.03 kJ/mol for
three consecutive experiments.
2.3. In vivo studies
Activity against infection with Plasmodium berghei (NK 65)
was used as a measure of antimalarial activity in vivo. Experi-
ments were performed according to the guidelines of the
Committee for Control and Supervision of Experiments on
Animals and approved by the Institutional Animal Ethics
Committee, Panjab University, Chandigarh. BALB/c mice
(age 4–5 weeks, weight 16–20 g) were provided with a standard
pellet diet and water ad libitum prior to experiments. Animals
were divided into 8 groups (n¼6 per group) and challenged
with an intraperitoneal (ip) injection of 106 P. berghei infected
red blood cells (RBCs) on day 1. They were then treated with a
single dose of arteether (6 mg/kg) suspended in 100 mL 0.5%
carboxymethylcellulose (CMC) or vehicle (control) twice a
day on day 1 and for 7 days thereafter. The mean percent
parasitemia (infected RBCs 100/total no. of RBCs) was mea-
sured every alternate day for up to 30 days. On each occasion,
a tail blood smear was taken, ﬁxed in methanol and stained with
Giemsa stain for counting of at least 500 cells.
2.4. Statistical analysis
Data are expressed as mean7standard deviation (SD). Para-
sitemia of arteether was assessed by one-way ANOVA followed
by Tukey’s test using Jandel Sigma Stat version 2.0. Differences
were considered signiﬁcant at Po0.05.Figure 1 DSC thermograms of the various crystal forms of
arteether: (a) commercial sample, (b) form I, (c) form II, (d) form
III, (e) form IV, (f) form V and (g) form VI.3. Results and discussion
3.1. Differential scanning calorimetry
DSC was used to conﬁrm the identity of the various crystal
forms and that there were no transformations during sample
preparation. Thermochemical parameters are given in Table 1.
The commercial drug sample showed a melting endotherm at
83.24 1C followed by a decomposition exotherm at 160.32 1C.
DSC scans of the various forms showed the absence of a
desolvation peak in the initial region of the thermogramsTable 1 Thermochemical parameters (DSC), solubilities, heats
arteether.
Sample Onset of
temp. (1C)
Peak
temp.
(1C)
Enthalpy of
fusion (J/g)
Decomposition
temp. (1C)
E
d
(J
Commercial
sample
81.61 83.24 60.65 160.32 4
Form I 68.62 78.91 50.34 159.31 5
Form II 70.52 81.71 50.12 158.77 4
Form III 76.90 82.37 39.05 163.93 4
Form IV 80.81 84.42 58.12 156.11 5
Form V 63.28 70.47 19.70 157.84 4
Form VI 82.13 83.87 65.34 163.41 5(Fig. 1) indicating that none of the forms were a solvate. All
forms exhibited a broad melting endotherm between 62 and
83 1C with signiﬁcant differences in their onsets and peaks and
a broad exotherm between 152 and 165 1C corresponding to
decomposition. The positions of the decomposition peaks andof solution and FT-IR peaks of various crystal forms of
nthalpy of
ecomposition
/g)
Solubility
(mg/
10 mL)
Heat of
solution
(kJ/mol)
FT-IR peaks
C–O–C
stretch
(cm1)
C–H
stretch
(cm1)
69.6 1.73 0.33 1192.9 2949.3
11.4 3.49 2.36 1202.4 2937.6
81.8 3.12 2.18 1207.3 2937.5
68.0 2.28 1.92 1205.8 2947.9
14.3 2.19 1.18 1199.2 2946.7
99.1 4.54 5.04 1203.4 2937.0
43.4 2.07 1.06 1202.6 2937.9
Renu Chadha et al.132their enthalpies of decomposition were signiﬁcantly different.
A broad endotherm with little enthalpy of fusion was observed
for form V suggesting it was the least crystalline form.
3.2. Scanning electron microscopy
Differences in crystal habit normally arise due to differences in the
environmental conditions of crystal growth, which lead to crystalsFigure 2 SEM images of the vari
Figure 3 PXRD of the various crystal forms of arteether: (a) commercia
and (g) form VI.with different external shapes but the same internal structure.
These differences in external shape include variation in size, the
relative development of certain faces and the kind and the number
of faces. SEM of the six forms of arteether revealed distinct
morphological features (Fig. 2). The SEM of the commercial
sample displayed prismatic crystals with thin ﬂat sheets or ﬂakes
peeling off the larger mass. Form I showed elongated ﬁne
crystalline plates resembling plumes. Form II showed pointedous crystal forms of arteether.
l sample, (b) form I, (c) form II, (d) form III, (e) form IV, (f) form V
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Investigation and characterization of various crystal forms of arteether 133needles and a ﬁlliform habit with thin pointed plates. Form III
also showed plates with angular edges. Form IV displayed long,
slender needle-like crystals. Form V showed an unorganized mass
with no discernible crystallinity. Form VI displayed a reticulated
habit with a lattice or network of small crystals.3.3. Powder X-ray diffraction
PXRD revealed that all forms were crystalline to various extents.
There was no signiﬁcant difference in the position of the peak
corresponding to 100% relative intensity (Fig. 3) but the relative
intensity of the various major peaks (Table 2) indicates that
all forms were less crystalline than the commercial sample.
Crystallinity decreased in the following order: commercial sam-
ple4form VI4form IV4form III4form II–form I4form V.3.4. Fourier transform infrared spectroscopy (FT-IR)
The various forms of arteether showed reproducible differ-
ences in the number and the position of absorption bands
in the FT-IR spectra (Table 1) with average band shifts of
2–15/cm. Signiﬁcant differences in the regions 3000–2800/cm
and 1000–1250/cm (Fig. 4) attributed to variation in the
arrangement of asymmetric C–H and C–O–C stretching
vibrations indicate differences in intermolecular interactions
in these regions.Figure 4 FT-IR spectra of the various crystal forms of arteether:
(a) commercial sample, (b) form I, (c) form II, (d) form III,
(e) form IV, (f) form V and (g) form VI.
Renu Chadha et al.1343.5. Solution calorimetry
All forms exhibited exothermic dissolution behavior. Calcu-
lated values of DHsol are given in Table 1. DHsol of form V was
found to be the most negative (5.04 kJ/mol) indicating
maximum ease of molecular release from the lattice and lowest
crystallinity. DHsol of the commercial sample was found to be
the least negative (0.33 kJ/mol) indicating minimum ease of
release from the lattice (i.e. the largest amount of energy to
break the lattice) and highest crystallinity.Figure 6 Percent parasitemia observed in P. berghei infected mice a
arteether (std drug¼commercial sample; tests 1–6¼ forms I–VI).
Table 3 Antimalarial activity of the various crystal forms of art
S. no. Group Treatment
1 Control group 0.5% CMC solution
2 Commercial sample Arteether(6 mg/kg)
3 Test group 1 Form I
4 Test group 2 Form II
5 Test group 3 Form III
6 Test group 4 Form IV
7 Test group 5 Form V
8 Test group 6 Form VI
aValues are expressed as mean7SD (n¼6); t: no. of days; PI: post-
Figure 5 Dissolution proﬁles of the various crystal forms of
arteether.3.6. Solubility studies
The solubility study shows that the most crystalline form
(commercial sample) was the least soluble (1.73 mg/10 mL) and
that the least crystalline form (form V) was the most soluble
(4.54 mg/10 mL) with a 2.62-fold increase in solubility (Table 2).
The order of increasing solubility is commercial sample4form
VI4form IV4form III4form II4form I4form V.
3.7. Dissolution studies
The dissolution curves of the different forms showed differ-
ences in the rate of dissolution consistent with the orders of
crystallinity, DHsol and solubility. The results of dissolution
studies are presented in graphical form as mean percentage
release vs. time (Figs. 5 and 6). The highest dissolution rate
was found for the most soluble form (form V).
3.8. Antimalarial activity
It is clear from the data presented in Table 3 that arteether does
not prevent mortality. However, it was found to increase survival
time (15–19 days) compared to control (10 days) due to
signiﬁcant reductions (Po0.001) in parasitemia. At the end of
treatment (day 8), percent parasitemia (Table 3) was in the
following order: control4commercial sample4form VI4form
IV4form III4form II4form I4form V. Mortality at 30 days
was in the following order: control4form VI–commercial sam-
ple4form IV4form II–form III4form V–form I.t various times after treatment with the various crystal forms of
eether against P. berghi infection in mice.
Mean % parasitemiaa
on day 8 PI
% Mortality at 30 days (n¼6)
59.6873.57 100
40.3972.03 63.3
18.5671.43 16.7
20.5570.55 33.3
25.3172.70 33.3
30.5672.03 50.0
16.5671.43 16.7
36.2973.25 63.7
inoculation.
Investigation and characterization of various crystal forms of arteether 1354. Conclusions
Crystallization of arteether under various conditions produced
six morphologically different forms. The forms were differ-
entiated by DSC, PXRD, FT-IR, solution calorimetry and
dissolution behavior. Highest solubility was observed for
form V, which also showed the highest antimalarial activity
with 83.3% survival after 30 days compared to 33.3% survival
for the commercially available form. This indicates that form
V obtained by crystallization from a mixture of DMSO and
H2O exhibits the highest bioavailability.
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